Race-neutral pulmonary function testing, now recommended by ATS and implemented at Boston Medical Center, has had a long road to acceptance.
Real-world use of antifibrotic therapy is associated with greater estimated survival in pulmonary fibrosis interstitial lung disease (PF-ILD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback